Software Engineer

Organization
Intellia Therapeutics
Job Location
Cambridge, MA 01826
Job Description

Intellia Therapeutics is seeking an experienced software engineer to support the development of CRISPR/Cas9 based therapeutics. You will work to develop a web based platform to expose the results of next-generation sequencing pipelines and R/python based tools for experimental design. This role will require blending experiences in cloud computing, software architecture, database design and maintenance, programming, and software deployment as well as interfacing with computational biologists and biologists to successfully build software which will be critical to developing CRISPR/Cas9 therapeutics.

Requirements

GENERAL RESPONSIBILITIES:

  • Lead the development of a web based software platform to expose analyses and tools

  • Work closely with the bioinformatics team to implement and deploy work flows and pipelines for handling NGS data

  • Work with scientists to develop and maintain software tools to meet their needs, as required

  • Implement, support, and optimize database solutions

  • Support screening and sequencing through the development of tools to automate processes and work flows, store data, and track samples (LIMS experience preferred)

 

REQUIRED SKILLS:

  • Demonstrated experience designing, coding, and deploying software

  • Previous experience in the life sciences, working with biological data is preferred

  • Demonstrated full stack web development experience, preferably using the cloud

 

QUALIFICATIONS:

  • BS or MS in bioinformatics, computer science, or engineering with 4+ years of experience

How to Apply
About Our Organization

The development of CRISPR/Cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. Adapted from a natural cellular process, CRISPR/Cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. Intellia was founded in 2014 by Caribou Biosciences and Atlas Venture, along with a consortium of leading scientists who have helped define the space. Intellia Therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of CRISPR/Cas9 technology for human therapeutic use.

 

New study finds bias against female lecturers among student course evaluations, the Economist reports.

A research duo finds that science and technology graduate students who turn away from academic careers do so because of changes in their own interests.

Students whose classmates are interested in science are more likely to think about a career in science, technology, engineering, and mathematics, a new study says.

CNBC reports that the genetic counseling field is expected to grow as personalized medicine becomes more common.